Prognostic significance of percentage of bronchioloalveolar pattern in adenocarcinomas of the lung.
暂无分享,去创建一个
[1] R. Welsh,et al. Prognostic factors in T1 NO MO adenocarcinomas and bronchioloalveolar carcinomas of the lung. , 1999, American journal of clinical pathology.
[2] V. Rusch,et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. , 1994, Chest.
[3] R. Figlin,et al. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer , 1999, Journal of Cancer Research and Clinical Oncology.
[4] A. Giordano,et al. Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. , 1999, American journal of respiratory cell and molecular biology.
[5] J. Minna,et al. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] W. Mooi,et al. The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. , 1996, Lung cancer.
[7] S. Reed,et al. Deregulated cyclin E induces chromosome instability , 1999, Nature.
[8] R. Sutherland,et al. Cyclins and breast cancer. , 1996, Cancer treatment and research.
[9] M. Fukuoka,et al. p53 status and prognosis in stage I-IIIa non-small cell lung cancer. , 1997, International journal of oncology.
[10] H. Matsuda,et al. Inversely correlated expression of p16 and Rb protein in non‐small cell lung cancers: An immunohistochemical study , 1996, International journal of cancer.
[11] J. Farber,et al. Analysis of cell type and radiographic presentation as predictors of the clinical course of patients with bronchioalveolar cell carcinoma. , 1998, Chest.
[12] B. Gasser,et al. Bronchoalveolar carcinoma: histopathologic study of evolution in a series of 105 surgically treated patients. , 1998, Chest.
[13] S. Kido,et al. Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma. , 1999, The Annals of thoracic surgery.
[14] I. Kawase,et al. Clinical significance of p53 in non-small-cell lung cancer. , 1999, Oncology reports.
[15] S. Piantadosi,et al. Recurrence and survival following resection of bronchioloalveolar carcinoma of the lung--The Lung Cancer Study Group experience. , 1989, Annals of surgery.
[16] S. Jiang,et al. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. , 1998, The American journal of pathology.
[17] A. Patchefsky,et al. Bronchoalveolar cell carcinoma of the lung. , 1986, The Annals of thoracic surgery.
[18] P. Pairolero,et al. Bronchoalveolar carcinoma: factors affecting survival. , 1991, The Annals of thoracic surgery.
[19] Y. Shimosato,et al. Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.
[20] T. Halazonetis,et al. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. , 1998, The American journal of pathology.
[21] K. Sugimachi,et al. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] D. Niewoehner,et al. Do molecular markers predict survival in non-small-cell lung cancer? , 1998, American journal of respiratory and critical care medicine.
[23] W. Richards,et al. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] C. Cordon-Cardo. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. , 1995, The American journal of pathology.
[25] E. Mark,et al. Bronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. , 1999, The Journal of thoracic and cardiovascular surgery.
[26] X. Liu,et al. G1 control gene status is frequently altered in resectable non‐small cell lung cancer , 1997, International journal of cancer.
[27] A. Marchetti,et al. Cyclin D1 and retinoblastoma susceptibility gene alterations in non‐small cell lung cancer , 1998, International journal of cancer.
[28] D. Sabiston,et al. Alveolar cell carcinoma of the lung: a retrospective analysis of 205 patients. , 1988, The Annals of thoracic surgery.
[29] Y. Yatabe,et al. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] D. Niewoehner,et al. Rb and p16INK4a expression in resected non-small cell lung tumors. , 1996, Cancer research.
[31] Elson Ce,et al. Morphologic and immunocytochemical studies of bronchioloalveolar carcinoma at Duke University Medical Center, 1968-1986. , 1989 .
[32] A. Marchetti,et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. , 1993, Cancer research.
[33] J. Sørensen,et al. Prognostic implications of histopathologic subtyping in patients with surgically treated stage I or II adenocarcinoma of the lung. , 1989, The Journal of thoracic and cardiovascular surgery.
[34] Y. Fujiwara,et al. Prognostic Significance of p53 and ras Gene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease after Curative Resection , 1994, Japanese journal of cancer research : Gann.
[35] J. Lee,et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] G. Hannon,et al. Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). , 1995, Cytogenetics and cell genetics.
[37] S. Barsky,et al. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features , 1994, Cancer.
[38] S. Rodenhuis,et al. Comparative analysis of p53 gene mutations and protein accumulation in human non‐small‐cell lung cancer , 1995, International journal of cancer.
[39] H. Ishida,et al. The prognostic significance of p53 and bcl‐2 expression in lung adenocarcinoma and its correlation with ki‐67 growth fraction , 1997, Cancer.
[40] Setsuo Hirohashi,et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis , 1995 .
[41] K. Yasumoto,et al. Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma , 1997, Cancer.
[42] G. Jianhua,et al. A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. , 1998, Cancer letters.
[43] J. Izbicki,et al. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer. , 1995, The Journal of thoracic and cardiovascular surgery.
[44] L. Santambrogio,et al. Prognostic significance of different biomarkers in non-small cell lung cancer. , 1999, Oncology reports.
[45] J. Paré,et al. Differentiating bronchioloalveolar carcinoma from adenocarcinoma. , 1982, The American review of respiratory disease.
[46] W. Benedict,et al. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] W. Benedict,et al. Altered retinoblastoma protein expression in nonsmall cell lung cancer , 1997, Cancer.
[48] J. Manning,et al. Bronchioloalveolar carcinoma: The significance of two histopathologic types , 1984, Cancer.